Next-Generation Sequencing Services Industry Overview

The global next-generation sequencing services market size is expected to reach USD 24.48 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 22.68% from 2024 to 2030. The development of next-generation sequencing (NGS) technologies has revolutionized gene sequencing in terms of reproducibility and cost savings. This has resulted in the introduction of several advancements in NGS technology to promote its usage in clinical labs and hospitals. Most current innovations in this field revolve around simplifying the usage of seq-technology and making it more sophisticated. These factors have driven the uptake of NGS services across various end-users.

Next-generation sequencing has progressed from research to clinical use in the last five years. Around 14 nations have launched large-scale genome sequencing programs, with nearly 60 million people expected to have their genome analyzed by 2025. Conventional disease testing service providers have broadened their portfolio with a rising trend of seq-based genetic tests. For instance, ARUP Laboratories announced the release of new coronavirus tests in March 2022, and IDbyDNA, Inc. partnered with another firm to introduce new coronavirus tests, an NGS test for respiratory illnesses, to aid physicians in evaluating patients with pneumonia and some other respiratory problems.

Gather more insights about the market drivers, restrains and growth of the Next-Generation Sequencing Services Market

With the rising trend of high throughput sequencing within the pharma and biotech industry, there is a need for more developments to improve the speed and convenience of high throughput seq-platforms and simplify workflows. As a result, companies are focusing on the development of solutions to simplify the amplification and purification of samples and starting input. In March 2022, Illumina, Inc. announced the release of TruSigh Oncology (TSO) Comprehensive (EU), a comprehensive diagnostic that evaluates several tumor genes and indicators to identify a patient's cancer's individual molecular profile. The in vitro diagnostic (IVD) kit would assist in influencing genomic decisions for patients with cancer across Europe, with its global debut taking place first in Europe.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global next-generation sequencing data analysis market size was valued at USD 999.4 million in 2024 and is expected to expand at a CAGR of 23.10% from 2025 to 2030.
  
  
• The global human embryonic stem cells market size was estimated at USD 2.20 billion in 2024 and is projected to grow at a CAGR of 10.44% from 2025 to 2030. 

Next-generation Sequencing Services Market Segmentation

Grand View Research has segmented the global next-generation sequencing services market report based on service type, workflow, end-use, and region

Next-generation Sequencing (NGS) Service Type Outlook (Revenue, USD Million, 2018 - 2030)

• Human Genome Sequencing Services
• Single Cell Sequencing Services
• Microbial Genome-based Sequencing Services
• Gene Regulation Services
  • Small RNA Sequencing
  • ChIP Sequencing
  • Other Gene Regulation-based Services
• Animal Plant Sequencing Services
• Other Sequencing Services

Next-generation Sequencing (NGS) Services Workflow Outlook (Revenue, USD Million, 2018 - 2030)

• Pre-sequencing
• Sequencing
• Data Analysis

Next-generation Sequencing (NGS) Services End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Universities Other Research Entities
• Hospitals Clinics
• Pharma Biotech Entities
• Others

Next-generation Sequencing (NGS) Services Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Switzerland
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
  • Singapore
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Key Companies profiled:

• Quest Diagnostics Incorporated
• ARUP Laboratories
• Applied Biological Materials, Inc. (abm)
• Novogene Co, Ltd.
• Azenta Life Sciences (GENEWIZ)
• NanoString
• Illumina, Inc.
• PacBio
• Veritas
• BGI (Beijing Genomics Institute)
• Gene by Gene Ltd.
• Lucigen Corporation

Key Next-Generation Sequencing Services Company Insights

The continuous demand for next generation sequencing services by multiple end-use has created numerous market opportunities for major players to capitalize on.

• In July 2023, The University of the Free State's Next Generation Sequencing (UFS-NGS) Unit, part of the Faculty of Health Sciences, recently hosted a successful Data Bioinformatics Workshop on the UFS's Bloemfontein Campus. The program was aimed to provide participants with the fundamental bioinformatics skills needed to analyze NGS data, with an emphasis on three areas: whole genome data, 16S/ITS metagenomics data, microbial metagenomics data.
• In November 2021, Novogene stated during the 44th Annual Gathering of Molecular Biological Society of Japan (MSBJ) in Japan that they will be launching single-cell sequencing services specifically for their Japanese customers. Novogene Japan K.K. will provide on-site service to assist clients in optimizing their single-cell planning with this new service.
• In November 2021, Illumina and Genetic Alliance announced iHope Genetic Program aspires to provide WGS (whole-genome sequencing) access to thousands of people suffering from genetic illness around the world. Majority of iHope Genetic Health's initiatives will be centered on areas of the globe in need beyond the U.S., with over one-third of Illumina's endorse being devoted to patients in Africa. This will help accelerate start-up operations and upgrade existing operations in terms of sequencing volume and efficiency.

Order a free sample PDF of the Next-Generation Sequencing Services Market Intelligence Study, published by Grand View Research.